

posaconazole tablet (NOXAFIL)
posaconazole oral suspension (NOXAFIL)

Diagnoses Considered for Coverage:

- Prophylaxis of invasive Aspergillosis in severely immunocompromised patients
- Prophylaxis of disseminated candidiasis in severely immunocompromised pts
- Treatment of oropharyngeal candidiasis

Coverage Criteria:

For prophylaxis against Aspergillus or Candida infection:

- Patient is severely immunocompromised, **and**
- Dose does not exceed FDA label maximum.

For esophageal or oropharyngeal candidiasis:

- Inadequate response, intolerable side effect, or has a medical reason for not using fluconazole, **and**
- Dose does not exceed FDA label maximum.

For treatment of invasive fungal infection due to Aspergillus, Fusarium or Zygomycetes:

- Culture positive for *Aspergillus*, *Fusarium*, or *Zygomycetes*, **and**
- Dose does not exceed compendia supported maximum.

For treatment of invasive fungal infection due to Candida:

- Culture is positive for *Candida*, **and**
- Dose does not exceed compendia supported maximum, **and**
- One of the following:
 - Insufficient response, intolerable side effect, or contraindication to fluconazole, **or**
 - Culture and sensitivity (C&S) results show fluconazole is ineffective.

For treatment of Allergic Bronchopulmonary Aspergillosis (ABPA):

- Insufficient response, intolerable side effect, or contraindication to itraconazole, **and**
- Dose does not exceed compendia supported maximum.

For treatment of pulmonary aspergillosis, chronic (cavitary or necrotizing):

- Insufficient response, intolerable side effect, or contraindication to itraconazole or voriconazole, **and**
- Dose does not exceed compendia supported maximum.

Coverage Duration:

Oropharyngeal candidiasis: up to 1 month

Prophylaxis against Aspergillosis or Candida: up to 1 year

Prophylaxis against Aspergillosis or Candida: Up to 1 year

Prophylaxis against Esophageal candidiasis: Up to 1 year (or until CD4 > 200 cells/ μ L)

Invasive fungal infections: Up to 1 year

ABPA: 4 months initially, reauthorization is based on clinical response

Treatment of pulmonary aspergillosis, chronic: Up to 1 year

Effective Date: 5/31/2023